Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4316274 | 0.99 | SIGMAR1 (0.50) | SIGMAR1HTTSMN1; SMN2TAAR1ADRB2 | |
| Hydrochloric Acid SCHEMBL4275546 | 0.99 | SIGMAR1 (0.50) | SIGMAR1HTTSMN1; SMN2TAAR1ADRB2 | |
| SCHEMBL4313357 | 0.77 | SIGMAR1 (0.48) | SIGMAR1HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4275544 | 0.76 | SIGMAR1 (0.47) | SIGMAR1HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4316272 | 0.76 | SIGMAR1 (0.47) | SIGMAR1HTTSMN1; SMN2 | |
| SCHEMBL4325393 | 0.76 | SCN5A (0.46) | HTTSMN1; SMN2TAAR1CALM1TAS1R3 | |
| SCHEMBL29342459 | 0.76 | SIGMAR1 (0.66) | SIGMAR1HTTSMN1; SMN2TAAR1ADRB2 | |
| SCHEMBL275640 | 0.76 | CHRM2 (0.59) | SIGMAR1HTTSMN1; SMN2TAAR1ADRB2 | |
| SCHEMBL19498809 | 0.75 | HTT (0.82) | SIGMAR1HTTSMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL6835324 | 0.74 | CHRM2 (0.56) | SIGMAR1HTTSMN1; SMN2TAAR1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285785-B1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | NOVARTIS AG (CH) | 2012-09-05 | — | — | EP | claimed |
| WO-2009138378-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | NOVARTIS AG (CH) | 2009-11-19 | — | — | WO | claimed |
| US-8664228-B2 | 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases | NOVARTIS AG (CH) | 2014-03-04 | — | — | US | disclosed |
| EP-2285785-B1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | NOVARTIS AG (CH) | 2012-09-05 | — | — | EP | disclosed |
| WO-2009138378-A1 | 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES | NOVARTIS AG (CH) | 2009-11-19 | — | — | WO | disclosed |